Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.
Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.
Exelixis/Ipsen’s novel combination of cabozantinib and atezolizumab has produced mixed top-line results from the Phase III COSMIC-312 study, and although the companies are pressing ahead with further analyses, the doublet may struggle to compete in the first-line advanced liver cancer setting.
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.